DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of soft tissue sarcoma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at the first line of therapy is also forecast across the major mature pharmaceutical markets.

DRG Epidemiology's soft tissue sarcoma forecast will answer the question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of soft tissue sarcoma over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following soft tissue sarcoma subpopulations:

  • Diagnosed prevalent STS cases—by resection status.
  • Diagnosed incident cases—all sites.
  • Diagnosed incident cases—by specific sites.
  • First-line drug-treatable cases.
  • … and more (details available on request).

Note: Coverage may vary by country.

Table of contents

  • Mature Markets
    • Introduction
      • Key Findings
        • Incidence of Soft Tissue Sarcoma per 100,000 per Year Among People of All Ages in 2018 and 2038
        • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Soft Tissue Sarcoma over the Next 20 Years
    • Epidemiology Data
    • Methods
      • Newly Diagnosed Incidence
      • Stage Distribution
      • Recurrent Incidence
      • Diagnosed Prevalence
      • Drug-Treatable Populations
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Johnson Olabisi, MBBS, MSc; Nishant Kumar, MPH

Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space. Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.  

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.


Related Reports

Soft Tissue Sarcoma | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key soft tissue sarcoma patien...

View Details

Soft Tissue Sarcoma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence...

View Details

Soft Tissue Sarcoma | Epidemiology | Americas

DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across the Americas (Argentina, Canada, Chile, Colombia, and Peru). We report...

View Details

Soft Tissue Sarcoma | Epidemiology | Europe

DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across Europe (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Ne...

View Details